GlaxoSmithKline Pharma Net Up 6 Percent (India)
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline's India division increased its net profit by 6 percent during second quarter 2007 compared to last year. The Indian division is developing four new anti-diabetic products, and this year has successfully launched two such products, Windia and Windamet. GSK's total sales fell by 2.1 percent, mostly due to the sale of Virbac Animal Health in 2006, one reason its operations efficacy and net profit increased in second quarter 2007. The company also is selling Qualigens Fine Chemicals to India-based Thermo Electron LLS India for Rs 240 crore. (Click here for more